This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I

$$R^6$$
 R^4
 R^2
 R^3

in which

R², R⁴ denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF₃, NO₂, CN, OCF₃, OA, NHA, NA₂, NH₂,

R³, R⁶ denote (CH₂)_nHet, (CH₂)_nAr,

R¹ denotes H or an organic radical, in particular $(CH_2)_n CO_2 R^5, (CH_2)_n COHet, CHO, (CH_2)_n OR^5, (CH_2)_n Het, (CH_2)_n N(R^5)_2, CH=N-OA, CH_2 CH=N-OA, (CH_2)_n NHOA, (CH_2)_n (R^5) Het, (CH_2)_n CH=N-Het, (CH_2)_n OCOR', (CH_2)_n N(R^5) CH_2 CH_2 OR^5, (CH_2)_n N(R^5) CH_2 CH_2 OCF_3, (CH_2)_n N(R^5) C(R^5) OCOR^5, (CH_2)_n N(R') CH_2 COHet, (CH_2)_n N(R^5) CH_2 Het, (CH_2)_n N(R^5) CH_2 CH_2 Het, (CH_2)_n N(R^5) CH_2 CH_2 N(R') CH_2 OCOR', (CH_2)_n N(R^5) CH_2 CH_2 N(R^5)_2, CH=CHCOOR^5, CH=CHCH_2 NR^5 Het, CH=CHCH_2 N(R^5)_2, CH=CHCH_2 OR^5 or (CH_2)_n N(R^5) Ar,$

R⁵ denotes H or A

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical

containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal,

Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR⁵, OOCR⁵, COOR⁵, COOR⁵, CF₃ or SO₂CH₃,

- X denotes CH or N,
- n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I

where, in the case that X has the meaning CH, R² and R⁴ do not simultaneously denote H,

or salts, solvates, enantiomers, racemates thereof or mixtures of enantiomers.

- 2. (Original) Compounds of the formula I according to Claim 1, in which R⁶ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.
- 3. (Previously Presented) Compounds of the formula I according to claim 1, in which R⁴ denotes H, Hal, CN, A or NO₂.
- 4. (Previously Presented) Compounds of the formula I according to claim 1, in which R² denotes H or alkyl.

- 5. (Previously Presented) Compounds of the formula I according to claim 1, in which R³ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.
- 6. (Previously Presented) Compounds of the formula I according to claim 1, in which X has the meaning N.
- 7. (Original) Compounds of the formulae IA, IB, IC, ID, IE and IF:

$$\mathbb{R}^4$$
 \mathbb{R}^4 \mathbb{R}^3 \mathbb{R}^3

$$R^6$$
 N OH IC

$$R^6$$
 N
 OH
 ID

in which

R³, R⁴, R⁶ and X have the meanings indicated in Claim 1.

8. (Previously Presented) Process for the preparation of compounds of the formula IA

in which R³, R⁴, R⁶, X and A have the meaning indicated in Claim 1 or salts or solvates thereof, comprising reacting a compound of the formula II

$$R^6$$
 $NHNH_2$

or acid-addition salts thereof in which R^4 , R^6 and X have the meanings indicated in Claim 1, with a compound of the formula III

in which

A and R³ have the meanings indicated in Claim 1, and/or converting a basic compound of the formula IA into one of its salts by treatment with an acid.

9. (Previously Presented) Process for the preparation of compounds of the formula

$$\mathbb{R}^4$$
 \mathbb{O} \mathbb{I} \mathbb{R}^3

in which R³, R⁴, R⁶, X and A have the meaning indicated in Claim 1 or salts or solvates thereof, comprising reacting a compound of the formula II

$$R^4$$
 $NHNH_2$

or acid-addition salts thereof in which R^4 , R^6 and X have the meanings indicated in Claim 1, with a compound of the formula IV

$$R^3$$
 O A IV

in which

ΙB

A and R³ have the meanings indicated in Claim 1, and/or converting a basic compound of the formula IB into one of its salts by treatment with an acid.

- 10. (Cancelled)
- 11. (Currently Amended) A method for the treatment or prophylaxis of diseases sleep

<u>disorders</u> mediated by the binding of the compounds I to 5 HT receptors, comprising administering to a host in need thereof a compound, salt, solvate, enantiomer, racemate or enantiomer mixture of claim 1.

- 12. (Cancelled)
- 13. (Currently Amended) A method according to claim 11, wherein the salt, solvate, enantiomer, racemate or enantiomer mixture has a 5-HT2A receptor-antagonistic action.
- 14. (Currently Amended) A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts and/or one of its solvates, and a pharmaceutically acceptable carrier.
- 15. (Currently Amended) A process for the preparation of a pharmaceutical composition, comprising combining a compound of the formula I according to Claim 1 and/or one of its physiological acceptable salts and/or one of its solvates into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.
- 16. (Currently Amended) A method for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, premenstrual syndrome and/or for positively influencing obsessive compulsive disorder (OCD), comprising administering to a host in need thereof a compound, salt, solvate, enantiomer, racemate or enantiomer enantiomer mixture of claim 1.
- 17. (Currently Amended) Compounds of formula I according to claim 1 in which Het denotes one of the following radicals:

18. (New) A method for the prophylaxis or treatment of schizophrenia or depression, comprising administering to a host in need thereof a compound, salt, enantiomer, racemate or enantiomer mixture of claim 1.